Endocrine Abstracts

Context: ß-CTX are considered useful markers of response to denosumab and other anti-resorbtive treatments for osteoporosis. We report an unusual case of a completely absent effect of both denosumab and bisphosphonates on bone resorption markers.Case description: In 2017 a 74-year-old woman sought medical attention at the Endocrinology Unit of Policlinico di Sant’Orsola for the evaluation of an adrenal adenoma associated with osteoporosis. Meno...

Cushing disease and hypophosphatasia are rare conditions that may be both responsible of an important impairment of bone metabolism with increased fracture risk. We reported for the first time a case of a 43-year-old woman that came at our attention for recent onset of alopecia and amenorrhea. At the anamnesis, she denied any past relevant events and no drug assumption. At the physical examination, she presented rubeosis and facies lunaris and central adipose distribution (wai...

Monoclonal antibodies against the Programmed cell death-1 protein (PD-1) are a new treatment for advanced cancer. Endocrine and metabolic diseases are known to be frequently associated with this class of drugs. We describe two cases of Nivolumab-induced diabetes mellitus.Case 1: A 73-year-old man with a mutated BRAF-V600K advanced stage melanoma was treated with Nivolumab (240 mg IV every 2 weeks). He had normal-weight (BMI: 21.6 Kg/mq), and no previous ...

Background: Immune checkpoint inhibitors (ICI) have become a clinically validated treatment for numerous types of tumor including melanoma, lung, and kidney carcinoma. These treatments can cause immune-related adverse events affecting several organs including the endocrine system.Aims: The aim of this study was to characterize the type and the onset of the ICI associated-endocrinopathies.Materials and methods: This retrospective co...